A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Public ClinicalTrials.gov record NCT03157128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Study identification
- NCT ID
- NCT03157128
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 857 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2, 2017 (Actual)
- Primary completion
- Feb 14, 2025 (Actual)
- Completion
- Feb 2027 (Estimated)
- Last update posted
- Apr 16, 2026
2017 – 2027
United States locations
- U.S. sites
- 41
- U.S. states
- 24
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic of Scottsdale | Scottsdale | Arizona | 85259 | — |
| City of Hope National Medical Center | Duarte | California | 91010-0269 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Kaiser Permanente | Oakland | California | 94611-5400 | — |
| Irvine Medical Center | Orange | California | 92868 | — |
| University of California - San Diego | San Diego | California | 92103 | — |
| UCSF Medical Center at Mission Bay | San Francisco | California | 94158 | — |
| Kaiser Permanente Medical Center | Walnut Creek | California | 94596 | — |
| Sarah Cannon Research Institute at HealthOne | Denver | Colorado | 80218 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| Memorial Hospital Pembroke | Pembroke | Florida | 33028 | — |
| Emory University | Atlanta | Georgia | 30329-5102 | — |
| University of Chicago Medicine-Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Mayo Clinic | Rochester | Minnesota | 55905-0002 | — |
| Washington University Medical School | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| NYU Langone | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University Hospital | Columbus | Ohio | 43210-1257 | — |
| Oregon Health and Science University | Portland | Oregon | 97201 | — |
| University of Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Sarah Cannon Research Institute SCRI | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6303 | — |
| University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | 75390-9063 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| USO-Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| University of Wisconsin-Madison Hospital and Health Clinic | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03157128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03157128 live on ClinicalTrials.gov.